Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$1.29
-$0.03(-2.33%)
At close: 4:00 PM EDT
$1.29
-$0.03(-2.33%)
Day’s Range― - ―
52-Week Range$1.21 - $7.22
Previous Close$1.26
Volume26.65K
Average Volume (3M)174.33K
Market Cap
$6.85M
Enterprise Value-$18.63
Total Cash (Recent Filing)$19.39M
Total Debt (Recent Filing)$667.94K
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageVery low leverage limits interest and refinancing pressure, giving NuCana greater flexibility to fund oncology development. This is a durable financial strength, although it does not eliminate the need for future capital because the company remains pre-revenue.
Improving Loss And Cash-Burn TrendThe narrowing operating cash outflow suggests tighter cost control or lower development spending than in earlier periods. If sustained, this can extend liquidity and reduce financing needs, though the company remains cash-flow negative and not self-funding.
Clinical Pipeline And Funding RunwayAn active oncology pipeline provides potential long-term value creation through clinical milestones, while the reported runway supports continued development without immediate operational disruption. Progress remains dependent on trial outcomes and future financing access.
Bears Say
No Product RevenueNuCana lacks recurring commercial revenue, so its financial outlook depends on clinical success, licensing, partnerships, or external capital. This makes future funding capacity and pipeline execution more important than operating scale over the next several months.
Persistent Operating LossesOngoing losses and negative free cash flow show that the business cannot currently fund research and development internally. Continued deficits will consume available resources and may constrain the pace of clinical programs unless burn reduction persists.
Shrinking Equity And Financing RiskThe substantial reduction in equity reflects cumulative losses and weakens the financial cushion supporting development. Reliance on registered financing capacity can preserve liquidity, but future equity issuance may dilute existing holders and remains a structural risk.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.21 and its highest was $7.22 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $6.85M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Nov 12, 2026 which is in 85 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.432%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.49% Other Institutional Investors
98.51% Public Companies and
Individual Investors